Tags: Drug.

Zanamivir INN /zəˈnæmɨvɪər/ is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A and B viruses. It was developed by the Australian biotech firm Biota. It was licensed to Glaxo in 1990 and approved in the US in 1999 only for use as a treatment for influenza. Later on in 2006 it was approved for prevention of influenza A and B. Zanamivir was the first neuraminidase inhibitor commercially developed.

Zanamivir_structure.svg
ATC prefix
J05
ATC suffix
AH01
Bioavailability
2.0
CAS number
139110-80-8
ChEBI
50663
DrugBank
DB00558
FDA UNII code
L6O3XI777I
IUPAC name
(2R3R4S)-4-guanidino-3-(prop-1-en-2-ylamino)-2-((1R2R)-123-trihydroxypropyl)-34-dihydro-2H-pyran-6-carboxylic acid
PubChem
60855

Loading...

This page contains content from the copyrighted Wikipedia article "Zanamivir"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.